Agios/$AGIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Ticker
$AGIO
Sector
Primary listing
Employees
540
Headquarters
Website
Agios Metrics
BasicAdvanced
$2.4bn
-
-$7.25
0.79
-
Price and volume
Market cap
$2.4bn
Beta
0.79
52-week high
$46.00
52-week low
$22.24
Average daily volume
1.2m
Financial strength
Current ratio
14.187
Quick ratio
12.799
Long term debt to equity
1.527
Total debt to equity
3.223
Profitability
EBITDA (TTM)
-470.266
Gross margin (TTM)
-436.76%
Net profit margin (TTM)
-639.84%
Operating margin (TTM)
-719.97%
Effective tax rate (TTM)
0.24%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-21.69%
Return on equity (TTM)
-32.82%
Valuation
Price to revenue (TTM)
35.239
Price to book
2.14
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
-5.896
Free cash flow yield (TTM)
-16.96%
Free cash flow per share (TTM)
-6.77
Growth
Revenue change (TTM)
78.34%
Earnings per share change (TTM)
-163.29%
3-year revenue growth (CAGR)
51.44%
10-year revenue growth (CAGR)
1.63%
3-year earnings per share growth (CAGR)
22.25%
10-year earnings per share growth (CAGR)
7.20%
What the Analysts think about Agios
Analyst ratings (Buy, Hold, Sell) for Agios stock.
Agios Financial Performance
Revenues and expenses
Agios Earnings Performance
Company profitability
Agios News
AllArticlesVideos
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
Investors Business Daily·1 week ago
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
MarketBeat·1 month ago
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.